Objective
Given the increasing use and broadening of indications for antipsychotic medications in the general population, as well as the paucity of information on the safety of this drug class during pregnancy, the study aim was to document patterns of antipsychotic medication use in pregnant women.
Method
Medicaid Analytic eXtract data (2001–2010) from pregnant women who delivered live-born infants was used. Antipsychotic use at both the class and individual drug level was defined based on dispensed outpatient prescriptions. Users’ characteristics, including mental disorder diagnoses, were described. Temporal trends in use, as well as discontinuation patterns and polytherapy with other psychotropic medications during pregnancy were evaluated.
Results
Among 1,522,247 pregnancies, the prevalence of atypical antipsychotic use at any time during pregnancy increased three-fold, from .4% to 1.3%, over the 10-year period while the use of typical antipsychotics remained stable around .1%. The increase in atypical use was largely driven by more frequent use in patients with bipolar disorder. Quetiapine and aripiprazole were the most frequently dispensed drugs, and polytherapy with antidepressants (65.2%), benzodiazepines (24.9%), and/or other mood stabilizers (22.0%) was common among women using antipsychotics during pregnancy. More than 50% of women receiving an antipsychotic in the 3 months prior to pregnancy discontinued during pregnancy.
Conclusions
A growing number of pregnant women in Medicaid are exposed to atypical antipsychotics, frequently in combination with other psychotropic medications. This study highlights the importance of documenting the use and safety of these drugs during pregnancy to inform therapeutic decision making for pregnant women with psychiatric disorders.